Login to Your Account



Zelos' Series B Round Nets $42M For PTH Drug Pipeline

By Jennifer Boggs


Thursday, May 19, 2005
Zelos Therapeutics Inc. raised $42.5 million in a Series B round to fund clinical trials of its next-generation parathyroid hormone (PTH) analogue in four indications. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription